Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies

SIMPLE SUMMARY: Immunotherapy development in pediatric AML has been slow due to the paucity of validated AML-specific targets. We recently identified mesothelin (MSLN) as a therapeutic target in pediatric AML. Mice receiving T cell engaging bispecific antibodies (BsAbs) targeting MSLN and CD3 achiev...

Descripción completa

Detalles Bibliográficos
Autores principales: Gopalakrishnapillai, Anilkumar, Correnti, Colin E., Pilat, Kristina, Lin, Ida, Chan, Man Kid, Bandaranayake, Ashok D., Mehlin, Christopher, Kisielewski, Anne, Hamill, Darcy, Kaeding, Allison J., Meshinchi, Soheil, Olson, James M., Kolb, Edward Anders, Barwe, Sonali P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657033/
https://www.ncbi.nlm.nih.gov/pubmed/34885074
http://dx.doi.org/10.3390/cancers13235964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657033/
https://www.ncbi.nlm.nih.gov/pubmed/34885074
http://dx.doi.org/10.3390/cancers13235964

Ejemplares similares